inm004
mAbexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Dec 16, 2017 (NCT03388216)
Timeline
Indications
Mechanism of action
- Shiga toxinImmunity, passive
Shiga toxin immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06389474 | Phase 3 | Aug 17, 2024 | Exeltis, immunova, KLIXAR |
| NCT05569746 | Phase 2 | Sep 28, 2022 | immunova, KLIXAR, Linical Co., Ltd., PHV LATAM |
| NCT04132375 | Phase 2/Phase 3 (Phase 3) | Jul 17, 2019 | Exeltis, immunova |
| NCT03388216 | Phase 1 | Dec 16, 2017 | Hospital Italiano de Buenos Aires, immunova |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| immunova | For profit | 4 | 4 | 3 | 2017 |
| Exeltis | For profit | 2 | 0 | 1 | 2019 |
| KLIXAR | For profit | 2 | 0 | 2 | 2022 |
| Hospital Italiano de Buenos Aires | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Linical Co., Ltd. | For profit | 1 | 0 | 1 | 2022 |
| PHV LATAM | Academic/Hospital | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1